KOVALTRY — The Confidence to Take Control
The only unmodified, full-length rFVIII offering the potential for as few as 2 infusions per week1*
Trial Results for KOVALTRY
Review efficacy and safety of KOVALTRY for adolescents and adults, as well as in previously treated children.
See the study results
Patient Stories
Hear from real patients about living with hemophilia A, and their experiences with KOVALTRY.
Explore real stories
Co-Pay and Support Programs
Find out about KOVALTRY co-pay and support programs, and how you may be able to save on your prescription.
Learn about these services
Meet Your Local Bayer Rep
Talk to your local Bayer Representative, who is here to connect you with answers, resources and events in the hemophilia A community.
Connect with your local Bayer
Representative for hemophilia A
support.
INDICATION FOR KOVALTRY®
KOVALTRY® is a medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.
KOVALTRY is used to treat and control bleeding in adults and children with hemophilia A. KOVALTRY can reduce the number of bleeding episodes in adults and children with hemophilia A when used regularly (prophylaxis). Your healthcare provider may give you KOVALTRY when you have surgery.
KOVALTRY is not used to treat von Willebrand Disease.
IMPORTANT SAFETY INFORMATION
You should not use KOVALTRY if you are allergic to rodents (like mice and hamsters) or any ingredients in KOVALTRY.
Tell your healthcare provider if you have heart disease or are at risk for heart disease.
The common side effects of KOVALTRY are fever, headache, and rash, in addition to inhibitors in patients who were not previously treated or minimally treated with Factor VIII products.
Your body may make antibodies, called “inhibitors” against KOVALTRY, which may stop KOVALTRY from working properly. If your bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.
Allergic reactions may occur with KOVALTRY. Call your healthcare provider right away and stop treatment if you get tightness of the chest or throat, dizziness, decrease in blood pressure, and nausea.
Tell your healthcare provider about any side effect that bothers you or that does not go away.
Call your healthcare provider right away if bleeding is not controlled after using KOVALTRY.
For additional important risk and use information, please see full Prescribing Information.
*Compared to other rFVIII products
References: 1. KOVALTRY [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2021.
